AADC (aromatic L-amino acid decarboxylase)
Assets acting on this target.
- Class
- Gene therapy (AAV vector encoding AADC)
- Notes
- mechanism wave 2026-08-24 (DeepSeek draft; registry text of NCT05765981 names the target); source: https://clinicaltrials.gov/study/NCT05765981
Related mechanisms
Converted by aromatic L-amino acid decarboxylase (AADC) to dopamine (1)aromatic L-amino acid decarboxylase (AAAD; DOPA decarboxylase) (1)Amino Acid (1)Central dopamine precursor (levodopa) and peripheral decarboxylase inhibitor (carbidopa/benserazide) (1)Glutamic acid decarboxylase (GAD) gene delivered to the subthalamic nucleus (1)
AADC (aromatic L-amino acid decarboxylase) drugs compared
2 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Eladocagene exuparvovec | PTC Therapeutics | gene therapy | Approved | Approved in AADC Deficiency |
| VGN-R09b | Shanghai Vitalgen BioPharma Co., Ltd. | gene therapy | Phase 1/2 | Phase 1/2 in Parkinson's Disease |